Medicines usable for treatment of COVID-19 disease | Italian Medicines Agency Aifa toggle bar Search Search keywords The Agency The Agency Mission and values Organisation Scientific and Economic Committee for Medicines Support and Coordination Secretariats and Advisory Committees International Collaborations EU Projects Legislation Forms Competition notices Resolutions Tenders and contracts Quality assurance Guarantee Committee Atti di notifica Associazioni dei pazienti AIFA Incontra Contacts Certified email COVID-19 COVID-19 Communications about COVID-19 COVID-19 Vaccines Medicines usable for treatment of COVID-19 disease Use of monoclonal antibodies for COVID-19 Use of antivirals for COVID-19 Monitoring of medicinal products used during the COVID-19 epidemic Clinical Trials - COVID-19 Compassionate Use Programs - COVID-19 Access to medicinal products Access to medicinal products Early access and off-label use Authorisation of medicinal products Medicine shortages Antibiotic medicinal products Biological medicinal products Vaccines Blood derivatives Generic medicinal products Biosimilar medicinal products Orphan medicinal products Advanced therapies Homeopathic medicinal products Allergens Medicinali di origine vegetale Ancillary medicinal substances incorporated in medical devices Safety of medicinal products Safety of medicinal products Pharmacovigilance National Pharmacovigilance Network Adverse Reactions to medicinal products Persons in charge of Pharmacovigilance European Eudravigilance System Accesso alle segnalazioni - ADRreports Regional pharmacovigilance funds Segnali di sicurezza Risk management measures Medicinal products subject to additional monitoring Quality and Inspections Quality and Inspections Quality defects Inspections and authorisations Qualified person Fight of pharmaceutical crime Research and Clinical trials Research and Clinical trials Clinical trials concerning medicinal products EU Regulation on Clinical trials National Observatory on Clinical Trials Registro Studi Osservazionali Comitati Etici Nazionali (CEN) Ethics Committees Coordination Centre Independent clinical research Mappa dei centri di Sperimentazione Clinica Pricing and reimbursement Pricing and reimbursement Negotiation and reimbursement Economic evaluations Monitoring Registers AIFA Notes Lists of Class A and Class H medicinal products Innovative medicinal products Transparency Lists Consumption and pharmaceutical expenditure Consumption and pharmaceutical expenditure The Medicines Utilization Monitoring Centre (OsMed) Governance of pharmaceutical expenditure Monitoring pharmaceutical expenditure Innovation and planning Innovation and planning Innovation and scientific advice Horizon scanning Information and communication Information and communication FarmaciLine Medical and scientific information FAQ Publications Communication campaigns Eventi AIFA Scientific Seminars Press releases Dossier AIFA Mobile APP AIFA APP Firstline AIFA - Antibiotici ABC della Ricerca Clinica Presentations and speeches Public consultations and documents Documents shared with scientific communities Calendario eventi Archivio AIFA data AIFA data OsMed Data Open Data Companies Section Companies Section Requests for authorisation of conferences and meetings Payment of fees and annual duties MA Electronic invoicing Application for reimbursement and pricing Access information Notifica concessionari di vendita Comunicazione prima commercializzazione Open governance Open governance Disposizioni Generali Organizzazione Consulenti e collaboratori Personale Bandi di Concorso Performance Enti controllati Attività e procedimenti Provvedimenti Bandi di gara e contratti Sovvenzioni, contributi, sussidi, vantaggi economici Bilanci Beni immobili e gestione patrimonio Controlli e rilievi sull'Amministrazione Servizi Erogati Pagamenti dell'Amministrazione Opere pubbliche Pianificazione e governo del territorio Informazioni ambientali Interventi straordinari di emergenza Altri Contenuti Medicines usable for treatment of COVID-19 disease Medicines usable for treatment of COVID-19 disease In this section AIFA provides updated information on medicines used outside clinical trials, such as those marketed for other indications which are made available to patients, even in the absence of a specific therapeutic indication for COVID-19, often based on rather limited scientific evidence. Precisely for the high level of uncertainty whereby these therapies are made available and considering the particular state of emergency with respect to a pandemic that we are learning to know day by day, it is deemed important to continuously update the information relating to the efficacy and safety tests which will gradually become available. For this purpose, the Agency’s Scientific Technical Committee has prepared cards to make clear the therapeutic guidelines within which it is possible to provide for a controlled and safe use of the pharmaceuticals used in the context of this emergency. The cards clearly report evidence of efficacy and safety available as of today, the interactions and recommended methods of use in COVID-19 patients. In the same format, the medicines are listed whose use is recommended to remain within controlled clinical trials. In preparing such cards, the most updated evidence available at the time was taken into account. Information sheets on drugs used for COVID-19 emergency and related prescription procedures Anakinra in the treatment of adult patients with COVID-19 [0.32 Mb] [PDF] > Baricitinib in the treatment of adult patients with COVID-19 [0.29 Mb] [PDF] > Sarilumab in the treatment of adult patients with COVID-19 [0.34 Mb] [PDF] > Tocilizumab in the treatment of adult patients with COVID-19 [0.34 Mb] [PDF] > Low molecular weight heparins in the therapy of adult patients with COVID-19 (last updated on 13/05/2021) [0.91 Mb] [PDF] > Azithromycin in the treatment of adult patients with COVID-19 (last updated on 05/05/2020) [0.33 Mb] [PDF] > Darunavir/cobicistat in the therapy of adult patients with COVID-19 (last updated on 17/07/2020) [0.78 Mb] [PDF] > Lopinavir/ritonavir in the therapy of adult patients with COVID-19 (last updated on 17/07/2020) [0.27 Mb] [PDF] > Hydroxychloroquine in the treatment of adult patients with COVID-19 (last updated on 22/12/2020) [0.48 Mb] [PDF] > Remdesivir in the therapy of adult patients with COVID-19 (last updated on 06/06/2022) [0.37 Mb] [PDF] > Corticosteroids in the therapy of adult patients with COVID-19 [0.36 Mb] [PDF] > Recommendations on medicines to be used in home management of COVID-19 cases AIFA recommendation on druges for the home management of COVID-19 (Updated 10/03/2023) [0.21 Mb] [PDF] > Treatments to be used in COVID-19 patients in hospital setting (latest version 06/06/2022) [0.28 Mb] [PDF] > Related links Gestione domiciliare dei pazienti con infezione da SARS-CoV-2" - aggiornamento del 10 febbraio 2022 AIFA communications 28/07/2023 Antivirals and monoclonal antibodies for COVID-19: the AIFA monitoring summary report is online 14/07/2023 Monitoring of antivirals for COVID-19: new report published 14/07/2023 Monitoring of monoclonal antibodies for COVID-19: weekly report published 09/06/2023 Monitoring of monoclonal antibodies for COVID-19: weekly report published 09/06/2023 Monitoring of antivirals for COVID-19: new report published 19/05/2023 Monitoring of antivirals for COVID-19: new report published 19/05/2023 Monitoring of monoclonal antibodies for COVID-19: weekly report published 05/05/2023 Monitoring of antivirals for COVID-19: new report published 04/05/2023 Monitoring of monoclonal antibodies for COVID-19: weekly report published 14/04/2023 Monitoring of monoclonal antibodies for COVID-19: weekly report published 13/04/2023 Monitoring of antivirals for COVID-19: new report published 28/03/2023 Monitoring of antivirals for COVID-19: new report published 23/03/2023 Monitoring of monoclonal antibodies for COVID-19: weekly report published 15/03/2023 Modifica Registro ANTIVIRALI ORALI COVID-19 10/03/2023 Monitoring of antivirals for COVID-19: new report published 09/03/2023 Monitoring of monoclonal antibodies for COVID-19: weekly report published 24/02/2023 Monitoring of antivirals for COVID-19: new report published 23/02/2023 Monitoring of monoclonal antibodies for COVID-19: weekly report published 09/02/2023 Monitoring of monoclonal antibodies for COVID-19: weekly report published 27/01/2023 Monitoring of antivirals for COVID-19: new report published All news Page 1 of 11 10 11 20 Items per Page Showing 1 - 20 of 210 results. ← First Previous Next Last → COVID-19 Communications about COVID-19 COVID-19 Vaccines Medicines usable for treatment of COVID-19 disease Use of monoclonal antibodies for COVID-19 Use of antivirals for COVID-19 Monitoring of medicinal products used during the COVID-19 epidemic Clinical Trials - COVID-19 Compassionate Use Programs - COVID-19 Share Nested Applications Highlights 21/04/2026 - Medicine Use: 2024 Regional Reports Now Available Online 17/04/2026 - From one-size-fits-all treatments to personalised care: the revolution in precision medicine TUTTE LE NEWS - IN EVIDENZA ALL NEWS News 13/04/2026 Medicine Shortage Communication on Endoxan (ciclofosfamide) 13/04/2026 Medicine Shortage Communication on Holoxan (ifosfamide) 27/03/2026 Biosimilars: AIFA webinar on the Third Position Paper All news Nested Applications Press From one-size-fits-all treatments to personalised care: the revolution in precision medicine All press releases Last tweets 📢 #AIFA comunica il calendario degli incontri nell’ambito delle iniziative dedicate al dialogo e al... Vai al post → 🔬 AIFA pubblica il dossier “Dalle terapie a taglia unica alle cure su misura: la rivoluzione della ... Vai al post → 🎙️ “Immagino un futuro in cui ciascuno di noi abbia un vero e proprio passaporto farmacogenetico, m... Vai al post → 💊 Quasi 4 cittadini su 10 hanno ricevuto almeno una prescrizione di #antibiotici nel 2024, con una ... Vai al post → ⚠️ Attenzione alle false cure miracolose Negli ultimi tempi si sta diffondendo un business pericol... Vai al post → #AIFA promuove l’ascolto e la trasparenza Approvati i Regolamenti di “AIFA Ascolta” e “AIFA Incontr... Vai al post → Go to Twitter profile Go to Twitter profile aifa_ufficiale Multimedia Medicina di precisione e appropriatezza prescrittiva Go to YouTube channel Cookie Bar Footer The agency Home Page FarmaciLine User participation and satisfaction Citizens' access Modulistica Open governance Acts of notification Legal notification TrovaNormeFarmaco Competition notices Tenders and contracts Contacts Via del Tritone, 181 00187 Roma Contacts Certified e-mail (PEC) contacts VAT number: 08703841000 Tax code: 97345810580 IPA AIFA code: aifa_rm IPA UCB code: UFE1TR FOLLOW US ON label.button.spotify Bluesky FEED RSS Feed Rss Cookie management Sezione Link Utili Legal notice Social Media Policy Dichiarazione di accessibilità Web accessibility Website statistics Online services go to beginning of content